Danaher’s guidance of double-digit top-line growth for 2021 provides upside opportunities that depend mostly on the success of vaccine rollouts, Barclays said.
Some insiders emphasize the importance of doing rapid turnaround testing of asymptomatic people, while others contend lab tests ought to be the modality of choice.
